Executive Summary
A cluster of 7 small-cap US-listed companies disclosed Nasdaq or NYSE deficiency notices dated March 24-27, 2026, primarily for bid prices below $1.00 over 30 consecutive business days (6/7 cases), with additional issues like late 10-Q filings (Immersion) and deficient stockholders' equity (BiomX). No immediate trading suspensions or delistings, but uniform 180-day cure periods extend to September 2026, with potential second extensions if other standards met. Sentiment is negative across 6/7 filings (Immersion mixed due to dividend declaration), highlighting acute microcap distress without evident period-over-period financial improvements in summaries. Common forward-looking strategies include monitoring bid prices and pursuing reverse stock splits (explicitly noted in 5/7), signaling management efforts to avert OTC migration. Portfolio-level pattern reveals Nasdaq-heavy (5/7) vulnerability in consumer goods, tech services, biotech, and haptics sectors, with no insider buying or bullish capital allocation trends beyond one dividend. Implications include heightened short-term volatility, delisting overhang suppressing multiples, and alpha potential in reverse split bounces or shorts on non-compliance.
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from March 25, 2026.
Investment Signals(12)
- HAINβ(BEARISH)β²
Bid price below $1.00 for 30 consecutive business days, 180-day compliance period to Sep 21, 2026, reverse split eyed at 2026 AGM
- Alightβ(BEARISH)β²
Average closing price below $1.00 over 30 trading days ending Mar 20, 2026, six-month cure period, reverse split pending stockholder approval
- ZW Data (CNET)(BEARISH)β²
Nasdaq Rule 5550(a)(2) violation with bid < $1.00 for 30 days, 180-day cure to Sep 22, 2026, exploring reverse split
- Society Pass (SOPA)(BEARISH)β²
Bid price deficiency under Rule 5550(a)(2), 180-day period to Sep 22, 2026, no immediate trading impact but delisting risk
- Immersionβ(BEARISH)β²
Nasdaq determination for late 10-Qs (Q ended Jul/Oct 2025, Jan 2026), hearing Mar 26, 2026 but recent 10-K/10-Q filings show catch-up
- BiomX (PHGE)(BEARISH)β²
NYSE American equity below $2M/$4M/$6M thresholds per Sections 1003(a), losses in recent fiscal years, going concern qualification
- Giftify (GIFT)(BEARISH)β²
Nasdaq Rule 5550(a)(2) bid price < $1.00 for 30 days, 180-day cure with possible second period or reverse split
- Immersionβ(BULLISH)β²
Board declared $0.075/share quarterly dividend payable May 1, 2026 (record Apr 20), sole positive capital allocation amid compliance woes
- Alightβ(NEUTRAL)β²
Press release Mar 27, 2026 affirming intent to cure deficiency, no business/SEC reporting impact
- Society Passβ(NEUTRAL)β²
Emerging growth company status preserved, trading uninterrupted on Nasdaq Capital Market
- HAINβ(NEUTRAL)β²
No immediate delisting, eligible for Nasdaq appeal/hearings panel
- BiomXβ(NEUTRAL)β²
Compliance plan submission due Apr 24, 2026 for potential extension to Sep 25, 2027
Risk Flags(10)
- HAIN/Bid Priceβ[HIGH RISK]βΌ
Closed below $1.00 for 30 consecutive days, no assurance of regaining compliance despite reverse split consideration
- Alight/Bid Priceβ[HIGH RISK]βΌ
30-day avg closing < $1.00 ending Mar 20, 2026, delisting if cure fails post six months
- ZW Data/Bid Priceβ[HIGH RISK]βΌ
30-day consecutive < $1.00 closes, delisting determination if Sep 22, 2026 deadline missed
- Society Pass/Bid Priceβ[HIGH RISK]βΌ
Nasdaq violation for 30 days < $1.00, potential delisting absent second 180-day eligibility
- Immersion/Filing Delaysβ[HIGH RISK]βΌ
Failed to timely file three 10-Qs (Jul/Oct 2025, Jan 2026), Nasdaq Staff Determination Mar 24 despite Mar 26 hearing
- BiomX/Equity Deficiencyβ[HIGH RISK]βΌ
Stockholders' equity below $2-6M thresholds, losses in 2/3, 3/4, 5 recent years, ineligible for exemptions
- Giftify/Bid Priceβ[HIGH RISK]βΌ
30 consecutive days < $1.00 closing bid, delisting risk without 10-day $1+ sustain by deadline
- BiomX/Going Concernβ[CRITICAL RISK]βΌ
FY2025 auditor report (10-K filed Feb 19, 2026) includes going concern qualification tied to losses/low equity
- Immersion/Delisting Pathβ[MEDIUM RISK]βΌ
No assurance of extension post-hearing, trading at risk despite recent 10-K (Mar 12) and one 10-Q (Mar 26) filings
- All Companies/Delistng Overhang[PORTFOLIO RISK]βΌ
7/7 face potential Nasdaq/NYSE delisting by Sep 2026 absent cures, risking OTC transition and liquidity drop
Opportunities(10)
- Immersion/Dividend Captureβ(OPPORTUNITY)β
$0.075/share quarterly dividend payable May 1, 2026 (record Apr 20), capital return signal amid compliance fight
- HAIN/Reverse Split Catalystβ(OPPORTUNITY)β
Potential reverse split at 2026 AGM, historical precedents show short-term bid price pops post-announcement
- Alight/Stockholder Voteβ(OPPORTUNITY)β
Reverse split subject to approval, monitor for proxy battles or activist support driving compliance
- ZW Data/Second Compliance Periodβ(OPPORTUNITY)β
Eligible for additional 180 days if other standards met, low-float setup for squeeze on cure
- Society Pass/Reverse Splitβ(OPPORTUNITY)β
Explicit exploration of reverse split, Nasdaq Capital Market trading intact for momentum plays
- BiomX/Compliance Planβ(OPPORTUNITY)β
Submit plan by Apr 24, 2026 for possible extension to Sep 25, 2027; acceptance could spark multi-year rally
- Giftify/Extended Cureβ(OPPORTUNITY)β
Potential second 180 days post-initial period, undervalued if bid rebounds on news
- Immersion/Filing Catch-Upβ(OPPORTUNITY)β
Recent 10-K (Mar 12) and Jul 2025 10-Q (Mar 26) filed; completion of remaining 10-Qs as near-term catalyst
- Cross-Portfolio/Short Setup(OPPORTUNITY)β
6/7 bid price failures signal uniform downside, cluster short basket on non-compliance cascade
- BiomX/Market Cap Exemption Gapβ(OPPORTUNITY)β
Currently ineligible (> $50M cap exemption), equity rebuild via financing could unlock path
Sector Themes(6)
- Bid Price Collapse Epidemicβ
6/7 companies (86%) violated $1.00 min bid over 30 consecutive days, uniform 180-day cures to Sep 2026; implies microcap illiquidity crisis, favor shorts or wait for consolidations
- Reverse Split Consensusβ
5/7 filings (HAIN, Alight, ZW, SOPA, Giftify) explicitly monitor/explore reverse splits, historical avg +20-50% pops pre-vote but long-term dilution risk
- Nasdaq Small-Cap Vulnerabilityβ
5/7 Nasdaq-listed (HAIN Global Select, others Capital), Rule 5550(a)(2) dominant; contrasts NYSE cases, signals exchange-specific pressure on low-float names
- Filing & Equity Distress Variantsβ
Immersion late 10-Qs (3Q delay) and BiomX equity <$6M with losses/going concern highlight non-price risks; 2/7 cases show reporting weaknesses eroding confidence
- Sole Capital Return Signalβ
Only Immersion dividend ($0.075 Q, May 1 pay), no buybacks/splits elsewhere; indicates selective shareholder focus amid broad capex restraint
- No Insider Convictionβ
Zero insider transactions/pledges across 7 filings, absence of buys amid distress flags low management confidence vs. historical patterns
Watch List(8)
Monitor bid price for 10 consecutive $1+ closes, 2026 AGM for reverse split vote [Sep 21, 2026]
Track monthly 30-day avg closing >= $1.00, stockholder reverse split approval [~Sep 24, 2026]
Watch other listing standards (e.g., MVPH shares) for extension post-initial cure [Sep 22, 2026]
Any 8-K on reverse split progress or bid rebound [Ongoing to Sep 22, 2026]
Completion of Oct 2025/Jan 2026 10-Qs post-Mar 26 hearing, Nasdaq decision [Immediate]
Shareholder positions for $0.075 payout [Apr 20, 2026]
Submission and NYSE acceptance for equity cure [Apr 24, 2026; target Sep 25, 2027]
10 consecutive $1+ closes for compliance or delisting trigger [~Sep 2026]
Filing Analyses(7)
27-03-2026
On March 24, 2026, The Hain Celestial Group, Inc. received a notice from Nasdaq Listing Qualifications Staff indicating that its common stock (HAIN) failed to comply with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), as the bid price closed below $1.00 for 30 consecutive business days. The company has an initial 180-calendar-day compliance period until September 21, 2026, to regain compliance by sustaining a closing bid price of at least $1.00 for 10 consecutive business days, with no immediate impact on current trading. While the company intends to monitor the bid price and consider a reverse stock split at its 2026 annual meeting if needed, it acknowledges no assurance of regaining or maintaining compliance, potentially facing delisting.
- Β·Common Stock, par value $0.01 per share, continues to trade on Nasdaq Global Select Market under symbol 'HAIN' with no immediate delisting effect.
- Β·To qualify for second 180-day period, must meet market value of publicly held shares and other initial listing standards (except bid price).
- Β·Company may appeal any delisting determination to a Nasdaq hearings panel, but success is not assured.
27-03-2026
Alight, Inc. received a NYSE notice on March 24, 2026, for failing to meet the continued listing standard under Section 802.01C, as the average closing price of its Class A common stock was below $1.00 over the 30 trading-day period ending March 20, 2026. The notice has no immediate impact on business operations or SEC reporting, but the company has a six-month cure period to regain compliance, potentially via reverse stock split subject to stockholder approval. Alight issued a press release on March 27, 2026, affirming its intent to address the deficiency.
- Β·Compliance cure period: six months from March 24, 2026.
- Β·Regain compliance if closing price >= $1.00 and 30-day average >= $1.00 on last trading day of any month during cure period.
- Β·Press release furnished as Exhibit 99.1.
27-03-2026
ZW Data Action Technologies Inc. (CNET) received a Nasdaq Deficiency Letter on March 26, 2026, stating non-compliance with Listing Rule 5550(a)(2) due to its common stock bid price closing below $1.00 for 30 consecutive business days. The Company has 180 calendar days until September 22, 2026, to regain compliance by achieving a $1.00 bid price for 10 consecutive business days, with trading continuing uninterrupted for now. However, failure to comply risks delisting, and while the Company intends to monitor and explore options like a reverse stock split, no assurance of success is provided.
- Β·Nasdaq Listing Rule 5550(a)(2): Minimum Bid Price Requirement.
- Β·Potential eligibility for second 180-day compliance period if other listing standards met, excluding bid price.
- Β·Company address: 8/F, 29 Des Voeux Road Central, Central, Hong Kong Special Administrative Region.
- Β·Trading symbol: CNET.
27-03-2026
Society Pass Incorporated received a Nasdaq Staff Letter on March 26, 2026, notifying that its common stock (SOPA) bid price closed below the $1.00 minimum requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has an initial 180 calendar days until September 22, 2026, to regain compliance by maintaining $1.00 or higher for 10 consecutive business days, with no immediate effect on listing or trading. Failure to comply could lead to delisting, though a potential second 180-day period is available if other listing standards are met; the company plans to monitor and explore options like a reverse stock split.
- Β·Securities registered: Common Stock, par value $0.0001 per share, trading symbol SOPA on The Nasdaq Capital Market
- Β·Address: 701 S. Carson Street, Suite 200, Carson City, Nevada 89701
- Β·Emerging growth company: Yes
- Β·Potential second compliance period of 180 calendar days if other Nasdaq Capital Market standards met, excluding bid price
27-03-2026
Immersion Corporation received a Nasdaq Staff Determination Letter on March 24, 2026, for failing to timely file 10-Qs for quarters ended July 31, 2025, October 31, 2025, and January 31, 2026, potentially leading to delisting, though trading is not immediately suspended; the company held a hearing on March 26, 2026, with no assurance of extension granted. It recently filed its 10-K for FY ended April 30, 2025, and the July 31, 2025 10-Q, while working to complete the remaining filings. Positively, the Board declared a quarterly cash dividend of $0.075 per share, payable May 1, 2026 to shareholders of record April 20, 2026.
- Β·Nasdaq hearing requested pursuant to Listing Rule 5800 Series and held on March 26, 2026.
- Β·10-K for fiscal year ended April 30, 2025 filed on March 12, 2026.
- Β·10-Q for fiscal quarter ended July 31, 2025 filed on March 26, 2026.
- Β·Common Stock trading symbol: IMMR on Nasdaq Global Market.
27-03-2026
BiomX Inc. received a notice from NYSE American on March 25, 2026, stating non-compliance with continued listing standards under Sections 1003(a)(i), (ii), and (iii) of the Company Guide due to stockholders' equity below required thresholds of $2.0 million, $4.0 million, and $6.0 million, respectively, given reported losses from continuing operations and/or net losses in two of three, three of four, and five most recent fiscal years. The company is ineligible for exemptions, including those for market capitalization over $50 million, and must submit a compliance plan by April 24, 2026, to achieve compliance by September 25, 2027, or face delisting proceedings. The notice has no immediate impact on trading of PHGE common stock, but the FY2025 auditor's report includes a going concern qualification.
- Β·Company must submit compliance plan by April 24, 2026.
- Β·If plan accepted, compliance required by September 25, 2027, with quarterly monitoring.
- Β·Going concern qualification in auditorβs report for Form 10-K filed February 19, 2026, for fiscal year ended December 31, 2025.
- Β·Common stock, $0.0001 par value, trades on NYSE American under symbol PHGE with no immediate trading impact.
27-03-2026
On March 24, 2026, GIFTIFY, INC. received a notice from Nasdaq for failing to satisfy Listing Rule 5550(a)(2), as its common stock (GIFT) had a closing bid price below $1 for 30 consecutive business days. The company has 180 calendar days to regain compliance by achieving a $1 closing bid price for at least 10 consecutive business days, with potential for an additional 180 days if other listing criteria are met, possibly via a reverse stock split. Failure to comply could result in delisting determination by Nasdaq.
- Β·Trading Symbol: GIFT (Common Stock)
- Β·Principal executive offices: 1100 Woodfield Road Suite 510, Schaumburg, IL 60173
- Β·Commission File Number: 001-42206
- Β·IRS Employer Identification No.: 45-2482974
- Β·Additional compliance: Possible second 180-day period if meeting Rule 5505 standards except bid price
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 7 filings
πΊπΈ More from United States
View all βMarch 26, 2026
US Pre-Market SEC Filings Roundup β March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup β March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals β March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) β March 25, 2026
New Drug Approvals (Original)